Ipca acquires Onyx Scientific
Broadens contract manufacturing capabilities
Ipca Laboratories of India has bought Onyx Scientific for around £4.6m (US$7.5m).
The Mumbai-based company, a contract manufacturer that produces finished dosage forms and active pharmaceutical ingredients, has operations in more than 110 countries. Exports account for nearly 55% of revenue.
Onyx Scientific will continue to operate out of its Silverbriar, Sunderland plant, which offers custom synthesis, solid-state chemistry, scale-up and cGMP manufacturing up to a few kilograms.
Ipca India provides contract manufacturing services through its Covenance business division. Onyx Scientific’s capabilities in chemistry services for medicinal, preclinical and Phase-I/II programmes will dovetail with Ipca’s in supporting Phase II to commercial scale programmes.
‘The combined entity of Onyx Scientific and the Covenance division of Ipca will offer customers comprehensive solutions,’ said Tony Flinn, chief executive at Onyx Scientific.
‘Early development projects can be delivered from Onyx Scientific’s UK site with speed and flexibility while optimisation, scale-up and competitive manufacturing for late phase projects can be carried out from Ipca’s locations in India.’
Pranay Godha, executive director at Ipca, added: ‘We can now offer integrated services across the pharmaceutical life cycle with optimal speed, quality and cost offering.’
